TIAA CREF Investment Management LLC grew its stake in shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) by 3.0% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 39,074 shares of the biopharmaceutical company’s stock after purchasing an additional 1,148 shares during the period. TIAA CREF Investment Management LLC owned approximately 0.17% of Esperion Therapeutics worth $1,808,000 as of its most recent SEC filing.
Other institutional investors and hedge funds also recently made changes to their positions in the company. Aperio Group LLC bought a new stake in Esperion Therapeutics during the second quarter worth about $249,000. SG Americas Securities LLC boosted its stake in Esperion Therapeutics by 74.5% during the second quarter. SG Americas Securities LLC now owns 7,008 shares of the biopharmaceutical company’s stock worth $324,000 after acquiring an additional 2,991 shares in the last quarter. American International Group Inc. boosted its stake in Esperion Therapeutics by 7.1% during the first quarter. American International Group Inc. now owns 8,814 shares of the biopharmaceutical company’s stock worth $311,000 after acquiring an additional 584 shares in the last quarter. US Bancorp DE boosted its stake in Esperion Therapeutics by 1.1% during the second quarter. US Bancorp DE now owns 9,856 shares of the biopharmaceutical company’s stock worth $457,000 after acquiring an additional 104 shares in the last quarter. Finally, Metropolitan Life Insurance Co. NY bought a new stake in Esperion Therapeutics during the first quarter worth about $385,000. 89.82% of the stock is currently owned by hedge funds and other institutional investors.
Esperion Therapeutics (NASDAQ:ESPR) last released its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.92) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.67) by ($0.25). During the same quarter last year, the company posted ($0.62) EPS.
ILLEGAL ACTIVITY WARNING: This piece of content was first published by Community Financial News and is the sole property of of Community Financial News. If you are accessing this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.com-unik.info/2017/11/03/tiaa-cref-investment-management-llc-increases-stake-in-esperion-therapeutics-inc-espr.html.
Several equities research analysts recently commented on ESPR shares. Stifel Nicolaus reissued a “buy” rating and set a $70.00 price objective (up previously from $60.00) on shares of Esperion Therapeutics in a research note on Thursday, August 10th. Deutsche Bank AG set a $64.00 price objective on shares of Esperion Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, August 9th. Jefferies Group LLC raised shares of Esperion Therapeutics from a “hold” rating to a “buy” rating and dropped their price objective for the stock from $85.00 to $55.00 in a research note on Tuesday, August 8th. BidaskClub lowered shares of Esperion Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Friday, August 4th. Finally, Northland Securities reiterated a “buy” rating and issued a $72.00 target price on shares of Esperion Therapeutics in a research note on Wednesday, October 4th. Six investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $58.92.
Esperion Therapeutics Profile
Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.
What are top analysts saying about Esperion Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Esperion Therapeutics Inc. and related companies.